Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.
Regulator and payer constituencies have recognized the immense potential of real world evidence (RWE) in accelerating our ability to answer important questions about the safety and effectiveness of medical treatments. The opportunity to capitalize on real world data (RWD)/RWE goes beyond the regulatory domain. Payer demand for evidence to support a product’s value proposition is growing, in part due to the proliferation of value-based reimbursement models. In addition, the 21st Century Cures Act mandates that the FDA explores the use of RWE to expand indications for approved drugs and to fulfill post-approval requirements.
With more than 15 years in evidence generation, UBC is poised to address the challenges of this emerging landscape and accelerate the time to generate meaningful and clinically rich evidence by:
UBC’s broad and agnostic perspective on the RWD landscape, as well as experience conducting database feasibility studies, enable the selection of the right data for the right purpose.
UBC database specialists evaluate electronic medical records (EMR), administrative claims, and specialty databases to determine strengths and weaknesses for use in RWE studies to answer key study questions. We provide:
UBC is an industry-recognized leader in innovative observational and pragmatic study design and execution. UBC excels in:
UBC’s technology allows you to: